Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials
We demonstrate the efficacy of SHP1705 against GSCs, which pose as a major source of chemoradiation resistance leading to poor GBM patient prognosis. Novel circadian clock compounds have high potential for targeting GBM as single agents or in combination with each other or current standard-of-care.
Authors
- Steve A. Kay (ORCID: https://orcid.org/0000-0002-0402-2878)
- Jeremy N. Rich (ORCID: https://orcid.org/0000-0001-7845-5302)
- Laura A. Solt
- Rex Moats (ORCID: https://orcid.org/0000-0002-5448-6988)
- Tsuyoshi Hirota (ORCID: https://orcid.org/0000-0003-4876-3608)
- Gevorg Karapetyan
- Priscilla Chan (ORCID: https://orcid.org/0000-0003-1338-363X)
- Theodore M. Kamenecka (ORCID: https://orcid.org/0000-0002-3077-0167)
- Jamie Cope
- Anahit Hovsepyan
- Seda Mkhitaryan
- Yoshiko Nagai
- Jiarui Wang (ORCID: https://orcid.org/0000-0003-0640-5554)
- Qiulian Wu
Institutions
- University of Southern California (US)
- Scripps Research Institute (US)
- Children's Hospital of Los Angeles (US)
- University of Pittsburgh (US)
- California Animal Hospital (US)
- Pharmaron (United Kingdom) (GB)
- Nagoya University (JP)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/neuonc/noaf089
- Citations
- 10
- Primary Topic
- Circadian rhythm and melatonin
- Type
- article
- Field-Weighted Citation Impact
- 9.15